Haisco Pharmaceutical (SHE:002653) said China's medical products regulator has accepted the investigational new drug application for HSK60002 tablets.
The drug was independently developed for treating inflammatory diseases, according to a Tuesday filing with the Shenzhen bourse.
Shares of the company fell 1% in recent trade.